Biotech | August 09, 2021
AstraZeneca Pharma India PAT at Rs 10.24 crores
Board declares interim dividend of Rs 2 per equity share
Board declares interim dividend of Rs 2 per equity share
This work has been published in the journal ‘ACS applied materials and interface’
Board approves fundraise of Rs 1500 crore
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
This robust growth has come despite the raging pandemic for most part of the quarter
Subscribe To Our Newsletter & Stay Updated
